QIASEQ
LIVE

Serial Number

79201919

Owner

QIAGEN GMBH

Attorney

Victoria Friedman

Filing Date

Oct 21, 2016

Add to watchlist:

No watchlists yet
View on USPTO

QIASEQ Trademark

Serial Number: 79201919 • Registration: 5288349

QIASEQ is a trademark filed by QIAGEN GMBH on October 21, 2016. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). The application is currently registered and active.

Owner Contact Info

QIAGEN GMBH (212 trademarks)

HILDEN D-4010 , DE

Entity Type: 03

Trademark Details

Filing Date

October 21, 2016

Registration Date

September 19, 2017

Published for Opposition

July 4, 2017

Goods & Services

Scientific apparatuses, instruments and devices, as well as their structural replacement parts and components, namely, laboratory devices for detecting genetic sequences, laboratory apparatus and instruments for extracting, isolating, separating, purifying, duplicating, sequencing and/or analyzing biopolymers, in particular, nucleic acids, proteins, DNA macromolecules and biologically active substances, electrical equipment for the genetic modification of cells for research purposes; software for use in scientific and medical research, namely, software for scientific analysis of genetic sequences; software for analysis of nucleic acids, in particular software for sequencing of nucleic acids, software for extracting, isolating, separating, purifying, duplicating, sequencing and/or analyzing biopolymers, in particular, nucleic acids, proteins, DNA macromolecules and biologically active substances

Diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, in particular diagnostics, for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing all for medical or veterinary purposes; chemical, biochemical and biotechnological preparations, in particular reagents, enzymes and buffer solutions for medical or veterinary purposes, namely, for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing all for medical or veterinary purposes; kits containing preparations of reagents, enzymes and buffer solutions for medical and veterinary diagnostic purposes, in particular for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing all for medical and veterinary diagnostic purposes

Chemical, biochemical and biotechnological products for industrial and scientific purposes, namely, diagnostic preparations except for human or veterinary medical purposes; non-medical reagents, enzymes and buffer solutions for scientific and/or medical research use, namely, for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing all for scientific or medical research use; kits comprising chemicals for sample preparation, modification and manipulation of cells for scientific purposes, other than for medical or veterinary use; kits comprising chemicals for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular nucleic acids of biological or biochemical sample material all for scientific purposes, other than for medical or veterinary use; kits comprising in particular chemicals for reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing for scientific purposes, other than for medical or veterinary use

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Apr 24, 2024 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Apr 24, 2024 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 23, 2024 APRE
TEAS SECTION 71 & 15 RECEIVED
Aug 30, 2023 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Sep 19, 2022 REM3
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 14, 2019 TCCA
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 10, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 12, 2018 FICS
FINAL DISPOSITION PROCESSED
Jan 12, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 19, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Sep 19, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 4, 2017 NPUB
PUBLISHED FOR OPPOSITION
Jul 4, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 14, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 27, 2017 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
May 23, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 13, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 13, 2017 CRFA
ASSIGNED TO LIE
May 13, 2017 ALIE
ASSIGNED TO LIE
Apr 21, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 6, 2017 TROA
REFUSAL PROCESSED BY IB
Mar 25, 2017 RFNT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 14, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 14, 2017 REAP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 4, 2017 RFCS
REFUSAL PROCESSED BY MPU
Mar 4, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 3, 2017 RFCR
NON-FINAL ACTION WRITTEN
Mar 2, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Feb 28, 2017 MAFR
ASSIGNED TO EXAMINER
Feb 24, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 24, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 23, 2017 REPR